Research for the future
At the foundation, we are convinced that INMEST can significantly improve quality of life for many people. We also believe that the best way to achieve this is through high-quality scientific research.
That’s why our work is focused on supporting such research—either by funding studies or by conducting research ourselves.
If you would like to support our work, we gratefully accept donations.
Our story
Our story began in 2017, when the foundation was established with a generous contribution from the businessman Per Blomster. Per’s interest in INMEST came from his search for treatment options for his mother’s COPD. During that search, he came across Jan-Erik Juto’s research, which eventually led to a meeting between the two.
Per’s mother got to try the treatment – and felt somewhat better. Whether it was due to the treatment, a placebo effect, or something else entirely is impossible to say, but Per’s curiosity was sparked. Regardless of how much of an effect INMEST had on his mother’s condition, he understood that this was something worth researching further.
But research requires funding. Often, that funding comes from large pharmaceutical companies. However, a method that could potentially replace a range of medications isn’t exactly a top priority for them. Fortunately, after a long and successful entrepreneurial career, Per was in a position to provide the foundation’s initial funding.
We are deeply grateful for that.
Our purpose
Our main goal is to increase awareness about the potential of vagus nerve stimulation (VNS) in general, and INMEST in particular. The foundation also works to make these possibilities available as quickly as possible. We believe this treatment method will, in the future, become an important complement to pharmaceuticals.
To achieve these goals, the Inmest Foundation conducts research studies in areas where effective medical treatments are lacking.
If smaller studies show promising results, we can, together with Abilion Medical Systems AB—the provider of INMEST equipment—offer investors the opportunity to support expanded studies through ownership or donations, helping the method achieve CE marking. This certification allows the method to be used in healthcare and benefit patients.
In addition to clinical research, we also study the mechanisms behind INMEST.
Our legally defined purpose reads as follows:
The foundation’s purpose is to support, through financial contributions or by organizing itself, scientific research conducted with the involvement of Jan-Erik Juto, or secondarily in his spirit. Priority is given to research exploring the potential of nasal nerve stimulation in chronic obstructive pulmonary disease, cardiovascular disease, rheumatic disease, neurodegenerative disease, and cancer. The foundation may award grants either on its own initiative or upon application, according to the rules set by the board.
You can read more about exactly how donations are used on our donation page, where we describe the long and complex process of conducting a medical study.
The foundation’s board members
Jan-Erik Juto
Our chairman, Jan-Erik, invented INMEST together with his nephew, Fredrik Juto. Jan-Erik also co-founded Abilion Medical Systems AB, the company developing the medical device used in the treatment.
He is a former adjunct professor at Karolinska Institutet, an ENT specialist at Karolinska University Hospital, and holds an MSc in Engineering Physics from KTH Royal Institute of Technology. Over the years, Jan-Erik has published numerous research articles—among them, a particularly relevant one on using INMEST for chronic fatigue syndrome.
Read the story behind INMEST.
Per Blomster
Per is the reason the foundation exists. He initiated its creation, and it was his donation that laid the groundwork when the foundation was established in 2017.
His philanthropy has been made possible through a long and successful career as an entrepreneur in the construction industry, as well as an investor and business angel.
Over the years, Per has also played an active role on the board, contributing to the development of the method, as well as handling planning and administrative tasks.
Alexander Juto
Alexander is a specialist doctor in neurology at Karolinska University Hospital. He is also the son of Jan-Erik Juto, making him well-acquainted with INMEST.
In 2021, Alexander earned his PhD with a dissertation on antibody-based disease-modifying treatments for MS (multiple sclerosis). He is currently part of Associate Professor Caroline Ingres’ research group at Karolinska Institutet, where he is conducting his postdoctoral research on autonomic dysfunction in amyotrophic lateral sclerosis (ALS).
https://ki.se/cns/forskning/avdelningen-for-neuro/om-avdelningen-for-neuro/mot-vart-team
The research group plans to conduct a study testing INMEST on ALS patients.
Tie Quiang-Li
Tie has a long, international career behind him. In 1991, he earned his PhD in physical chemistry from the Royal Institute of Technology (KTH). In 1997, he became an associate professor at KTH in the same field. Between these milestones, he pursued postdoctoral studies at the University of California, Davis, and conducted research at Stanford University, Princeton, and Indiana University. From 1998 to 2008, he worked for the U.S. equivalent of the Public Health Agency, the NIH. Since 2008, he has been a hospital physicist at Karolinska University Hospital in Huddinge and an adjunct professor at Karolinska Institutet.
Fredrik Källmark
Fredrik Källmark, with a PhD from Karolinska Institutet, runs Källmarkskliniken, a specialist clinic for patients with dry eyes. For the past seven years, he has conducted research on vagus nerve stimulation using INMEST for dry eyes.
Since the start of his career as an optometrist in 1982, Fredrik’s goal has been to bring clinical research into everyday clinical practice, ensuring it benefits patients. That’s why he strives to obtain approval to use INMEST as quickly as possible in his clinical work.
Källmarkskliniken has ongoing research planned with INMEST for conditions such as Sjögren’s syndrome, glaucoma, and macular degeneration. The promising results make it crucial to continue research to understand the underlying mechanisms of INMEST.
